Detecting Chemosensitivity and Predicting Treatmemt Efficacy With CTCs in mNPC

Launched by SUN YAT-SEN UNIVERSITY · Sep 7, 2020

Keywords

ClinConnect Summary

This clinical trial is looking at how well a specific type of cancer responds to treatment by studying circulating tumor cells (CTCs) in patients with metastatic nasopharyngeal carcinoma (mNPC). CTCs are cancer cells that have broken away from the main tumor and are found in the bloodstream. By analyzing these cells, the researchers hope to understand how sensitive a patient's cancer is to chemotherapy and predict how effective the treatment will be. The study will involve 50 patients who have experienced cancer spread after receiving initial radiation therapy and are not suitable for further local treatments.

To be eligible for this trial, participants need to be between 18 and 70 years old and have at least one measurable area of cancer spread. They should also have a good performance status, meaning they are relatively healthy and can carry out daily activities. Patients who are pregnant, have other serious health issues, or are participating in other clinical trials will not be able to join. Those who enroll can expect to provide blood samples for testing and will be monitored for changes in their CTCs throughout the study. This trial aims to improve treatment decisions for patients with advanced nasopharyngeal cancer by better understanding their individual responses to chemotherapy.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • NPC patients with distant metastasis after 3 months of primary radiotherapy, and not suitable for local treatment
• • At least having one measurable metastatic lesion
• • All genders，range from 18～70 years old
• • ECOG score 0 \~ 1
• • Expected survival time ≥ 3 months
• • White blood cell(WBC) count ≥ 3×109/L, neutrophile granulocyte(NE) count ≥ 1.5×109/L, hemoglobin(HGB) ≥ 90g/L, platelet(PLT) count ≥ 100×109/L
• • Alanine aminotransferase (ALT) or aspartate aminotransferase(AST) \< 2.5×upper limit of normal(ULN), bilirubin(BUN) or creatinine(CRE) \< 1.5×ULN, alanine aminotransferase (CCR) ≥ 60ml/min
• • Inform consent form
• Exclusion Criteria:
• • Have or are suffering from other malignant tumors;
• • Participating in other clinical trials;
• • Drug or alcohol addition;
• • Do not have full capacity for civil acts;
• • Mental disorder;
• • Pregnancy or lactation;
• • Severe complication, eg, uncontrolled hypertension.